Testing three HBV medicines for severe liver flare (ACLF)
Treatments studied
Part of Digestive system, Infections clinical trials.
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hepatitis B: either a positive hepatitis B surface antigen test, or detectable hepatitis B virus DNA
- You are between 12 and 65 years old
- Your bilirubin level is very high (more than 10 times the normal upper limit)
- Your blood clotting is impaired (prothrombin time activity under 40% or prothrombin time ratio above 1.5)
- You have not taken HBV nucleotide/nucleoside medicines in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
This study tests two daily doses of the medicine entecavir to see which one better controls the hepatitis B virus in people with advanced liver scarring (cirrhosis). It aims to find the most effective dose to improve liver health.
This study compares two ways of managing hepatitis B while you receive immunotherapy for liver cancer: one group gets a single antiviral drug (TAF), the other gets two antiviral drugs (ETV and TAF). The goal is to see which approach better supports the immunotherapy and improves outcomes.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
This study tests whether adding a new drug called HRS-5635 to your current hepatitis B medicine works better than your current treatment alone. You may qualify if your hepatitis B is already controlled with antiviral pills and your viral levels are very low.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.